ReviewBreathe (Sheffield, England)2020
Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials.
Review in Breathe (Sheffield, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis.American journal of preventive medicine · 2025Pooled it
- An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening.Future oncology (London, England) · 2025Pooled it
- Pooled it
- Pooled it
- Lung Cancer Screening With Low-Dose Computed Tomography.Deutsches Arzteblatt international · 2023Pooled it
- The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.International journal of cancer · 2022Pooled it
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.The Cochrane database of systematic reviews · 2022Pooled it
- Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.PloS one · 2025Trial
- Geographic disparities and health inequality evolution in the disease burden of tracheal, bronchus, and lung cancer in Asia: a 33-year longitudinal analysis and future projections.Annals of medicine · 2026Article
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Incidence and mortality trends after introduction of lung cancer screening in a community-based healthcare system.Cancer epidemiology · 2026Article
- Evaluation of benign and malignant pulmonary nodules based on clinical and contrast-enhanced computed tomography data: a multicenter study.Quantitative imaging in medicine and surgery · 2026Article
- Innovative approaches for lung cancer screening and interception.Nature reviews. Clinical oncology · 2026Review
- Overdiagnosis in Lung Cancer Screening: Still the Unavoidable Cost of Doing Business?Annals of thoracic surgery short reports · 2025Article
- Managing incidental findings in total body PET/CT studies: balancing ethical considerations and resource constraints.EJNMMI reports · 2025Article
- A novel composite model for distinguishing benign and malignant pulmonary nodules.Clinical and experimental medicine · 2025Article
- Economic evaluation of low-dose computed tomography for lung cancer screening among high-risk individuals - evidence from Hungary based on the HUNCHEST-II study.BMC health services research · 2024Article
- Article
- Ethical Dimensions of Population-Based Lung Cancer Screening in Canada: Key Informant Qualitative Description Study.Public health ethics · 2024Article
- Real-world first round results from a charity lung cancer screening program in East Asia.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; and 3) eligible screening participants have a high risk of dying from causes other than lung cancer. The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time bias and without contamination of the control group. Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because lung cancer incidence after the end of screening was not published. Two other RCTs using active comparators were also excluded. Therefore, five RCTs were included: two trials were at low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-detected cancers were overdiagnosed. There is uncertainty about this substantial degree of overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate across the two trials. KEY POINTS: Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were identified; five were included for meta-analysis but only two of those were at low risk of bias.In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed.There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained heterogeneity and low precision of the point estimate.If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial. EDUCATIONAL
aimsTo appreciate that low-dose computed tomography screening for lung cancer meets all three main conditions for overdiagnosis in cancer screening: a reservoir of indolent cancers exists in the population; the screening test is able to "tap" this reservoir by detecting biologically indolent cancers as well as biologically important cancers; and the population being screened is characterised by a relatively high competing risk of death from other causesTo learn about biases that might affect the estimates of overdiagnosis in randomised controlled trials in cancer screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.